WO2020005068A8 - Gene signatures and method for predicting response to pd-1 antagonists and ctla-4 antagonists, and combination thereof - Google Patents

Gene signatures and method for predicting response to pd-1 antagonists and ctla-4 antagonists, and combination thereof Download PDF

Info

Publication number
WO2020005068A8
WO2020005068A8 PCT/NL2019/050401 NL2019050401W WO2020005068A8 WO 2020005068 A8 WO2020005068 A8 WO 2020005068A8 NL 2019050401 W NL2019050401 W NL 2019050401W WO 2020005068 A8 WO2020005068 A8 WO 2020005068A8
Authority
WO
WIPO (PCT)
Prior art keywords
ctla
gene signatures
antagonists
antagonist
antibody
Prior art date
Application number
PCT/NL2019/050401
Other languages
French (fr)
Other versions
WO2020005068A2 (en
WO2020005068A3 (en
Inventor
Oscar Krijgsman
Daniel Simon Peeper
Original Assignee
Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis filed Critical Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis
Publication of WO2020005068A2 publication Critical patent/WO2020005068A2/en
Publication of WO2020005068A8 publication Critical patent/WO2020005068A8/en
Publication of WO2020005068A3 publication Critical patent/WO2020005068A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

The present invention relates to the field of cancer, more particularly to the field of immunotherapy and gene signatures. Provided are two specific and distinct gene signatures, namely a Response Immune Signal (RIS) gene signature and a Stromal Immune Signal (SIS) gene signature, which can be used as biomarkers to accurately predict the response of a cancer subject to treatment with a PD-1 antagonist (e.g., PD-1 antibody) and/or a CTLA-4 antagonist (e.g., CTLA-4 antibody). In particular, it was found that the RIS and SIS gene signatures of the invention may be used in combination to predict the response of a cancer subject to treatment with a combination therapy consisting of a PD-1 antagonist (e.g., PD-1 antibody) and a CTLA-4 antagonist (e.g., CTLA-4 antibody). The gene signatures of the invention may be advantageously used in methods for treating cancer, such as melanoma, and to help devise treatment strategies best suited to individual patients (e.g., to achieve personalized therapy, and spare patients from undesired side effects, e.g., toxicity).
PCT/NL2019/050401 2018-06-29 2019-06-28 Gene signatures and method for predicting response to pd-1 antagonists and ctla-4 antagonists, and combination thereof WO2020005068A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2021209 2018-06-29
NL2021209 2018-06-29

Publications (3)

Publication Number Publication Date
WO2020005068A2 WO2020005068A2 (en) 2020-01-02
WO2020005068A8 true WO2020005068A8 (en) 2020-02-06
WO2020005068A3 WO2020005068A3 (en) 2020-04-02

Family

ID=67544304

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2019/050401 WO2020005068A2 (en) 2018-06-29 2019-06-28 Gene signatures and method for predicting response to pd-1 antagonists and ctla-4 antagonists, and combination thereof

Country Status (1)

Country Link
WO (1) WO2020005068A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021228888A1 (en) * 2020-05-12 2021-11-18 Asylia Diagnostics Biomarkers for hyperprogressive disease and therapy response after immunotherapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101899114A (en) 2002-12-23 2010-12-01 惠氏公司 Anti-PD-1 antibody and uses thereof
EP1869216B1 (en) * 2005-04-13 2012-08-15 Oncotest GmbH Gene expression profiles being predictive for the response of tumors to pharmaceutically effective compounds
CA2970873C (en) 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2008109075A2 (en) * 2007-03-05 2008-09-12 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
EP3222634A1 (en) 2007-06-18 2017-09-27 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
KR20110074850A (en) 2008-08-25 2011-07-04 앰플리뮨, 인크. Pd-1 antagonists and methods of use thereof
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
EP2920325A2 (en) * 2012-11-15 2015-09-23 Bristol-Myers Squibb Company Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent
US20160312295A1 (en) * 2013-12-17 2016-10-27 Merck Sharp & Dohme Corp. Gene signature biomarkers of tumor response to pd-1 antagonists
EP3084003A4 (en) 2013-12-17 2017-07-19 Merck Sharp & Dohme Corp. Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonists
WO2016094377A1 (en) * 2014-12-09 2016-06-16 Merck Sharp & Dohme Corp. System and methods for deriving gene signature biomarkers of response to pd-1 antagonists
WO2017161188A1 (en) * 2016-03-16 2017-09-21 The Regents Of The University Of California Detection and treatment of anti-pd-1 therapy resistant metastatic melanomas
US20170321285A1 (en) * 2016-05-03 2017-11-09 The Texas A&M University System Nlrc5 as a biomarker for cancer patients and a target for cancer therapy
WO2017201036A1 (en) * 2016-05-17 2017-11-23 Genentech, Inc. Stromal gene signatures for diagnosis and use in immunotherapy

Also Published As

Publication number Publication date
WO2020005068A2 (en) 2020-01-02
WO2020005068A3 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
EP3839510A3 (en) Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
CY1123957T1 (en) COMBINATION THERAPY FOR CANCER
WO2018017864A3 (en) Pvrig-binding agents and uses thereof
PH12018500233A1 (en) Single domain antibody programmed death-ligand (pd-l1) and derived protein thereof
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
NZ738008A (en) Tigit-binding agents and uses thereof
MX2018006973A (en) Humanized anti-cd73 antibodies.
MX2017012616A (en) A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same.
MX2016010067A (en) TARGETED TGFß INHIBITION.
WO2016014688A3 (en) Anti-pd-1 antibodies
ZA201807920B (en) Anti¿gitr antibodies and uses thereof
SG10201901057UA (en) Anti-pd-l1 antibodies
WO2015094995A3 (en) Gene signature biomarkers of tumor response to pd-1 antagonists
WO2012166617A3 (en) Methods, compositions, and kits for the treatment of cancer
WO2018031490A3 (en) Anti-ox40 binding proteins
NZ724815A (en) Humanized antibodies that bind lgr5
MX2019012192A (en) Diagnostic and therapeutic methods for cancer.
WO2016065349A3 (en) Short non-coding protein regulatory rnas (sprrnas) and methods of use
WO2019105468A8 (en) Methods for using cd137 ligand as a biomarker for treatment with anti-cd137 antibody
WO2015187018A3 (en) Means and methods for determining t cell recognition
PH12020550013A1 (en) Bispecific anti pd1-anti tim3 antibodies
MX2018012939A (en) BINDING MOLECULES SPECIFIC FOR FCyGAMMA RIIA AND USES THEREOF.
AU2018269892A8 (en) NMR methods and systems for the rapid detection of Candida species
EP4273165A3 (en) Interferon beta antibodies and uses thereof
WO2018069871A3 (en) Anti-kras binding proteins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19749830

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19749830

Country of ref document: EP

Kind code of ref document: A2